The 36-month beta value for DAWN is also noteworthy at -1.51. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for DAWN is 60.62M, and at present, short sellers hold a 16.98% of that float. The average trading volume of DAWN on July 04, 2024 was 1.18M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
DAWN) stock’s latest price update
The stock of Day One Biopharmaceuticals Inc (NASDAQ: DAWN) has increased by 0.30 when compared to last closing price of 13.46. Despite this, the company has experienced a 0.45% gain in its stock price over the last five trading sessions. zacks.com reported 2024-06-19 that Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.
DAWN’s Market Performance
Day One Biopharmaceuticals Inc (DAWN) has experienced a 0.45% rise in stock performance for the past week, with a 2.43% rise in the past month, and a -13.46% drop in the past quarter. The volatility ratio for the week is 4.05%, and the volatility levels for the past 30 days are at 5.08% for DAWN. The simple moving average for the last 20 days is 2.94% for DAWN stock, with a simple moving average of -2.51% for the last 200 days.
Analysts’ Opinion of DAWN
Many brokerage firms have already submitted their reports for DAWN stocks, with Needham repeating the rating for DAWN by listing it as a “Buy.” The predicted price for DAWN in the upcoming period, according to Needham is $33 based on the research report published on April 24, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see DAWN reach a price target of $9, previously predicting the price at $34. The rating they have provided for DAWN stocks is “Underperform” according to the report published on April 25th, 2023.
CapitalOne gave a rating of “Overweight” to DAWN, setting the target price at $40 in the report published on February 08th of the previous year.
DAWN Trading at -7.26% from the 50-Day Moving Average
After a stumble in the market that brought DAWN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.29% of loss for the given period.
Volatility was left at 5.08%, however, over the last 30 days, the volatility rate increased by 4.05%, as shares surge +5.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.22% lower at present.
During the last 5 trading sessions, DAWN rose by +0.45%, which changed the moving average for the period of 200-days by -3.02% in comparison to the 20-day moving average, which settled at $13.15. In addition, Day One Biopharmaceuticals Inc saw -7.53% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DAWN starting from Ramasastry Saira, who sale 10,000 shares at the price of $13.19 back on Jun 21 ’24. After this action, Ramasastry Saira now owns 40,485 shares of Day One Biopharmaceuticals Inc, valued at $131,877 using the latest closing price.
Blackman Samuel C., the HEAD OF R&D of Day One Biopharmaceuticals Inc, sale 30,000 shares at $12.62 during a trade that took place back on Jun 10 ’24, which means that Blackman Samuel C. is holding 1,141,081 shares at $378,588 based on the most recent closing price.
Stock Fundamentals for DAWN
Current profitability levels for the company are sitting at:
- -405.31 for the present operating margin
- -0.05 for the gross margin
The net margin for Day One Biopharmaceuticals Inc stands at -373.1. The total capital return value is set at -0.76. Equity return is now at value -69.97, with -64.27 for asset returns.
Based on Day One Biopharmaceuticals Inc (DAWN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -568.66. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -65.56.
Currently, EBITDA for the company is -205.68 million with net debt to EBITDA at 1.15. When we switch over and look at the enterprise to sales, we see a ratio of 1624.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.93.
Conclusion
In summary, Day One Biopharmaceuticals Inc (DAWN) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
